News

Pharma Logistics Masterclass Recognized in Tokyo as Momentum Builds for 5th Edition in Japan

[vc_row][vc_column][vc_column_text] Pharma.Aero has released the White Paper presenting the key findings of the Medical Devices Regulations (MDR) Project. This collaborative effort focused on the evolving regulations governing the medical devices sector.

Read here the White Paper of the MDR Project

The MDR Project combined a thorough examination of the medical device regulatory landscape in the EU, an impact assessment on logistics service providers, and a detailed gap analysis between MDR and Good Distribution Practices (GDP).

Results and Implications

The medical device sector within the EU is highly dynamic and competitive, with over 500,000 types of medical devices and in vitro diagnostic medical devices (IVDs), categorized based on risk, usage duration, and invasiveness. The White Paper outlines the roles and responsibilities of various economic operators, including manufacturers, importers, distributors, and authorized representatives.

Impact on Logistics Service Providers

One of the key conclusions is that logistics service providers (LSPs) are not classified as economic operators under the MDR, as they do not assume ownership of the medical devices. However, the transition from the Medical Device Directive (MDD) to the MDR has indirectly influenced LSPs, especially those already serving the pharmaceutical sector. These providers have had to update their Quality Management Systems (QMS) to meet new requirements from contracting companies, although they are not directly affected by the MDR.

Opportunities for Logistics Service Providers

The MDR Project highlights several opportunities for LSPs to support economic operators in the medical device sector:

  • Facilitating market entry
  • Managing returns
  • Handling special (hazardous) materials

A comprehensive analysis and detailed list of these opportunities are presented in the MDR Project’s Technical Report, available exclusively to Pharma.Aero members.

By investing in understanding the regulations and requirements faced by medical device companies, LSPs can enhance their value chain and unlock new business opportunities.

Special thanks to all our Pharma.Aero members and partners contributing to this project.
PLMC 2025 speakers at Belexpo June 2025

The 2025 edition of the Pharma Logisticst Masterclass marks a strategic collaboration between Pharma.Aero, the University of Antwerp, Kansai Airports, ANA Cargo, and NX GROUP (Nippon Express Group).On Thursday, June 19th, several of our upcoming speakers offered a powerful preview of what to expect this September at the Masterclass durin a panel session hosted by the Belexpo – the Belgian Pavilion at World Expo in Osaka. Entitled “Global Health, Local Strengths – Connecting Centers of Excellence in R&D and Pharma Logistics”, the session focused on how cutting-edge logistics, academic research, and real-world innovation are shaping the future of global health. Highlights included contributions from:

  • Prof. Wouter Dewulf – Academic Director, Centre for Maritime & Air Transport Management, University of Antwerp & Antwerp Management School

  • Prof. Roel Gevaers – University of Antwerp & Antwerp Management School

  • Prof. Shinya Hanaoka – School of Environment and Society, Tokyo Institute of Technology

  • Prof. Pierre Van Damme – Director, Vaccinopolis & Centre for the Evaluation of Vaccination, University of Antwerp

  • Frank Van Gelder – Secretary General, Pharma.Aero

This growing momentum reflects the Masterclass’s role as a global hub for bridging academia and industry in pharma logistics.

The Pharma Logistics Masterclass offers a unique opportunity to engage with thought leaders, explore the latest in supply chain innovation, and network with peers from around the world. The 2025 edition marks a strategic collaboration between Pharma.Aero, the University of Antwerp, Kansai Airports, ANA Cargo, and NX GROUP (Nippon Express Group).

My cart
Your cart is empty.

Looks like you haven't made a choice yet.